Equities Analysts Set Expectations for PCRX FY2027 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Pacira BioSciences in a research report issued to clients and investors on Thursday, March 20th. Zacks Research analyst R. Department expects that the company will post earnings of $2.45 per share for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share.

Other equities analysts have also issued reports about the stock. Barclays upped their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. HC Wainwright lifted their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price objective for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Finally, Needham & Company LLC lifted their price target on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $27.22.

Pacira BioSciences Stock Performance

Pacira BioSciences stock opened at $24.84 on Monday. The stock has a 50-day simple moving average of $24.52 and a 200 day simple moving average of $19.68. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -12.24 and a beta of 0.86. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $31.67.

Hedge Funds Weigh In On Pacira BioSciences

A number of large investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new position in Pacira BioSciences during the fourth quarter worth about $20,266,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Pacira BioSciences in the fourth quarter valued at about $8,558,000. Balyasny Asset Management L.P. acquired a new stake in shares of Pacira BioSciences during the 4th quarter worth about $8,180,000. Nuveen Asset Management LLC boosted its holdings in shares of Pacira BioSciences by 109.9% during the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company’s stock worth $11,792,000 after buying an additional 327,754 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after buying an additional 288,662 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.